410 related articles for article (PubMed ID: 37759536)
1. Inborn Errors of Metabolism with Ataxia: Current and Future Treatment Options.
Bremova-Ertl T; Hofmann J; Stucki J; Vossenkaul A; Gautschi M
Cells; 2023 Sep; 12(18):. PubMed ID: 37759536
[TBL] [Abstract][Full Text] [Related]
2. A master protocol to investigate a novel therapy acetyl-L-leucine for three ultra-rare neurodegenerative diseases: Niemann-Pick type C, the GM2 gangliosidoses, and ataxia telangiectasia.
Fields T; Patterson M; Bremova-Ertl T; Belcher G; Billington I; Churchill GC; Davis W; Evans W; Flint S; Galione A; Granzer U; Greenfield J; Karl R; Kay R; Lewi D; Mathieson T; Meyer T; Pangonis D; Platt FM; Tsang L; Verburg C; Factor M; Strupp M
Trials; 2021 Jan; 22(1):84. PubMed ID: 33482890
[TBL] [Abstract][Full Text] [Related]
3. Movement Disorders in Treatable Inborn Errors of Metabolism.
Ebrahimi-Fakhari D; Van Karnebeek C; Münchau A
Mov Disord; 2019 May; 34(5):598-613. PubMed ID: 30557456
[TBL] [Abstract][Full Text] [Related]
4. Acetyl-leucine slows disease progression in lysosomal storage disorders.
Kaya E; Smith DA; Smith C; Morris L; Bremova-Ertl T; Cortina-Borja M; Fineran P; Morten KJ; Poulton J; Boland B; Spencer J; Strupp M; Platt FM
Brain Commun; 2021; 3(1):fcaa148. PubMed ID: 33738443
[TBL] [Abstract][Full Text] [Related]
5. Treatable Ataxias: How to Find the Needle in the Haystack?
Stezin A; Pal PK
J Mov Disord; 2022 Sep; 15(3):206-226. PubMed ID: 36065614
[TBL] [Abstract][Full Text] [Related]
6. Effects of acetyl-DL-leucine on cerebellar ataxia (ALCAT trial): study protocol for a multicenter, multinational, randomized, double-blind, placebo-controlled, crossover phase III trial.
Feil K; Adrion C; Teufel J; Bösch S; Claassen J; Giordano I; Hengel H; Jacobi H; Klockgether T; Klopstock T; Nachbauer W; Schöls L; Stendel C; Uslar E; van de Warrenburg B; Berger I; Naumann I; Bayer O; Müller HH; Mansmann U; Strupp M
BMC Neurol; 2017 Jan; 17(1):7. PubMed ID: 28068987
[TBL] [Abstract][Full Text] [Related]
7. [Inborn errors of metabolism in adult neurology].
Sedel F
Rev Neurol (Paris); 2013 Feb; 169 Suppl 1():S63-9. PubMed ID: 23452774
[TBL] [Abstract][Full Text] [Related]
8. Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes.
Vogel AP; Folker J; Poole ML
Cochrane Database Syst Rev; 2014 Oct; (10):CD008953. PubMed ID: 25348587
[TBL] [Abstract][Full Text] [Related]
9. Beneficial Effects of Acetyl-DL-Leucine (ADLL) in a Mouse Model of Sandhoff Disease.
Kaya E; Smith DA; Smith C; Boland B; Strupp M; Platt FM
J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32276303
[TBL] [Abstract][Full Text] [Related]
10. Current and Promising Therapies in Autosomal Recessive Ataxias.
Picher-Martel V; Dupre N
CNS Neurol Disord Drug Targets; 2018; 17(3):161-171. PubMed ID: 29676235
[TBL] [Abstract][Full Text] [Related]
11. Autosomal recessive cerebellar ataxias.
Palau F; Espinós C
Orphanet J Rare Dis; 2006 Nov; 1():47. PubMed ID: 17112370
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Acetyl-DL-Leucine in Certain Types of Cerebellar Ataxia: The ALCAT Randomized Clinical Crossover Trial.
Feil K; Adrion C; Boesch S; Doss S; Giordano I; Hengel H; Jacobi H; Klockgether T; Klopstock T; Nachbauer W; Schöls L; Steiner KM; Stendel C; Timmann D; Naumann I; Mansmann U; Strupp M;
JAMA Netw Open; 2021 Dec; 4(12):e2135841. PubMed ID: 34905009
[TBL] [Abstract][Full Text] [Related]
13. Treatment and Management of Autosomal Recessive Cerebellar Ataxias: Current Advances and Future Perspectives.
Salem IH; Beaudin M; Klein CJ; Dupré N
CNS Neurol Disord Drug Targets; 2023; 22(5):678-697. PubMed ID: 35440322
[TBL] [Abstract][Full Text] [Related]
14. Update on the Pharmacotherapy of Cerebellar Ataxia and Nystagmus.
Feil K; Bremova T; Muth C; Schniepp R; Teufel J; Strupp M
Cerebellum; 2016 Feb; 15(1):38-42. PubMed ID: 26519380
[TBL] [Abstract][Full Text] [Related]
15. N-acetyl-L-leucine for Niemann-Pick type C: a multinational double-blind randomized placebo-controlled crossover study.
Fields T; M Bremova T; Billington I; Churchill GC; Evans W; Fields C; Galione A; Kay R; Mathieson T; Martakis K; Patterson M; Platt F; Factor M; Strupp M
Trials; 2023 May; 24(1):361. PubMed ID: 37248494
[TBL] [Abstract][Full Text] [Related]
16. Aminopyridines and Acetyl-DL-leucine: New Therapies in Cerebellar Disorders.
Kalla R; Strupp M
Curr Neuropharmacol; 2019; 17(1):7-13. PubMed ID: 30182858
[TBL] [Abstract][Full Text] [Related]
17. The neuropsychiatry of inborn errors of metabolism.
Walterfang M; Bonnot O; Mocellin R; Velakoulis D
J Inherit Metab Dis; 2013 Jul; 36(4):687-702. PubMed ID: 23700255
[TBL] [Abstract][Full Text] [Related]
18. Neurodegenerative Cerebellar Ataxia.
Rosenthal LS
Continuum (Minneap Minn); 2022 Oct; 28(5):1409-1434. PubMed ID: 36222772
[TBL] [Abstract][Full Text] [Related]
19. Keys to overcoming the challenge of diagnosing autosomal recessive spinocerebellar ataxia.
Arias M
Neurologia (Engl Ed); 2019 May; 34(4):248-258. PubMed ID: 27460185
[TBL] [Abstract][Full Text] [Related]
20. Laboratory investigations.
Boltshauser E; Weber KP
Handb Clin Neurol; 2018; 154():287-298. PubMed ID: 29903445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
